#United States #New York #ESSA Pharma #Levi Korsinsky #EPIX

Levi & Korsinsky Alerts Shareholders of Class Action Deadline

Levi & Korsinsky, LLP is reaching out to investors in ESSA Pharma Inc. (NASDAQ: EPIX) regarding a significant class action securities lawsuit affecting shareholders. This legal action is centered around allegations of securities fraud and seeks to provide financial recovery for those impacted.

Background of the Case

The lawsuit is particularly focused on investors who held shares in ESSA Pharma Inc. from December 12, 2023, until October 31, 2024. The case addresses serious claims suggesting that the company provided misleading information related to their product, masofaniten. The allegations state that this drug, when used in combination with enzalutamide, did not demonstrate the efficacy that was promised, potentially leading to financial losses for investors. The lawsuit claims that the defendants had misrepresented the effectiveness of their prostate cancer treatment, asserting that the treatment was expected to meet certain clinical endpoints which it ultimately failed to achieve.

Key Allegations

The specific claims within the lawsuit spotlight the following key concerns:

• - The treatment underperformed when compared to enzalutamide alone.
• - Evidence from the M-E Combination Study indicated that treatment outcomes were not up to the expectations set by the company.
• - Excessive claims were made regarding the product's clinical, regulatory, and commercial potential.
• - As a result of these misleading statements, investors suffered considerable financial losses.

Important Deadlines

For any investor who experienced losses during the relevant timeframe, it is crucial to note that the deadline to request appointment as the lead plaintiff is March 25, 2025. Notably, involvement in the lawsuit does not require being appointed as a lead plaintiff to potentially receive compensation.

No Financial Burden for Investors

Levi & Korsinsky emphasizes that participating in the class action does not involve any out-of-pocket costs for class members. Investors claiming losses are urged to come forward without any financial risk, as the firm is dedicated to ensuring no costs are borne by the individuals seeking recovery.

Why Choose Levi & Korsinsky?

With over two decades of experience in securities litigation, Levi & Korsinsky is recognized for having secured hundreds of millions for shareholders in complex cases. Their team is well-equipped with the expertise necessary to navigate the challenging landscape of securities fraud and has consistently ranked among the top securities litigation firms in the United States according to ISS Securities Class Action Services.

Contact Information

Investors looking for additional information or wishing to join the lawsuit are encouraged to reach out directly. Legal representatives from Levi & Korsinsky can be contacted via their office:

• - Contact: Joseph E. Levi, Esq.
• - Phone: (212) 363-7500
• - Address: 33 Whitehall Street, 17th Floor, New York, NY 10004
• - Email: info@zlk.com

In summary, the upcoming deadline for the ESSA Pharma securities class action lawsuit is a pivotal point for investors to seek accountability for any potential losses they may have incurred during the relevant period. This opportunity to join a class action provides a structured pathway toward possible financial recovery.